» Articles » PMID: 28210505

Nanotechnology-Based Approach in Tuberculosis Treatment

Overview
Publisher Wiley
Date 2017 Feb 18
PMID 28210505
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called . Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.

Citing Articles

Expanding horizons in theragnostics: from oncology to multidisciplinary applications.

Wu R, Zhu W, Shao F, Wang J, Li D, Tuo Z Radiol Med. 2025; .

PMID: 40042756 DOI: 10.1007/s11547-025-01971-7.


Advancing Nanotechnology: Targeting Biofilm-Forming Bacteria with Antimicrobial Peptides.

Campos J, Pontes J, Canales C, Roque-Borda C, Pavan F BME Front. 2025; 6:0104.

PMID: 40041091 PMC: 11876546. DOI: 10.34133/bmef.0104.


Biomolecular Interaction of Carnosine and Anti-TB Drug: Preparation of Functional Biopeptide-Based Nanocomposites and Characterization through In Vitro and In Silico Investigations.

Nagarajan U, Naha A, Ashok G, Balasubramanian A, Ramaiah S, V Kanth S ACS Omega. 2025; 10(1):567-587.

PMID: 39829512 PMC: 11739970. DOI: 10.1021/acsomega.4c07176.


Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.

Fernandez-Garcia R, Fraguas-Sanchez A Pharmaceutics. 2025; 16(12.

PMID: 39771562 PMC: 11677881. DOI: 10.3390/pharmaceutics16121584.


Therapeutic Potential of Silver Nanoparticles (AgNPs) as an Antimycobacterial Agent: A Comprehensive Review.

Barua N, Buragohain A Antibiotics (Basel). 2024; 13(11).

PMID: 39596799 PMC: 11591479. DOI: 10.3390/antibiotics13111106.


References
1.
Moretton M, Glisoni R, Chiappetta D, Sosnik A . Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces. 2010; 79(2):467-79. DOI: 10.1016/j.colsurfb.2010.05.016. View

2.
Horvath C, Shaler C, Jeyanathan M, Zganiacz A, Xing Z . Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells. Mucosal Immunol. 2012; 5(4):420-31. DOI: 10.1038/mi.2012.19. View

3.
Rohde K, Yates R, Purdy G, Russell D . Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev. 2007; 219:37-54. DOI: 10.1111/j.1600-065X.2007.00547.x. View

4.
Sharma A, Pandey R, Sharma S, Khuller G . Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents. 2004; 24(6):599-604. DOI: 10.1016/j.ijantimicag.2004.07.010. View

5.
Pandey R, Khuller G . Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother. 2006; 57(6):1146-52. DOI: 10.1093/jac/dkl128. View